Response from Lieberman and Colleagues
Several of the scientists who responded to our paper (1) raised similar questions, mostly showing a concern about the high doses used in our study. However, we would like to point out that, to the best of our knowledge, our paper is the first to examine the LD50 of cyclosiloxanes (CSs). While there may be a difference of opinion about the interpretation of these data, for the first time there are data to discuss. Of equal importance is that we provide data on doses lower than the LD50. These data demonstrate elevated serum enzyme values and histopathologic changes following administration of CSs and CS-D4 at nonlethal doses (0.1 mL/mouse; -3.5 g/kg). All of these considerations underscore the value of our work. Other studies have used similar doses and the same route of administration (0.1-lmL intraperitoneally) to examine the toxicity of organic compounds including siloxanes (2) (3) (4) . In our studies, no effects were noted when 1 mL soy oil was administered as a control. Our studies were intended to examine the acute toxicity of these agents rather than to evaluate their chronic toxicity or to determine the minimal level at which they produced a toxic effect.
Another concern raised by readers was Witschi also suggests that the phrase "cyclosiloxanes are widely distributed" is a misinterpretation of our data because only 0.1-0.5% is found in different organs (8) . The term "widely distributed" is used not as an index of the abundance of CSs in different organs but as a statement of their presence. We would also like to point out that we only measured unmetabolized CSs in these studies. If these compounds were modified by biotransformation and existed as new, low-molecular species or bound to macromolecules, we would not have detected them by our analysis. Further, most studies of siloxanes until recently were carried out without any quantitative assessment, that is, tissue level of siloxanes versus tissue injury (9) . In recognition of this problem, our group has developed methods for the detection and quantitation of cyclosiloxanes in biological tissues (1J).
Carlton and Meeks raise the issue of the preparation of the distillate and the fact that the "cracking" process at 1800C has no relationship to breakdown in the intact implant in vivo. In our paper we made no inferences about the relationship of distillate preparation to breakdown. Rather, we used the distillation process as a convenient way to produce a mixture of siloxanes, which we found migrated out of intact implants (11) . We could have just as easily purchased the components from a chemical company, and in fact, that is what we did with the octamethylcyclotetrasiloxane (CS-D4). This purchased CS-D4 produced effects that were indistinguishable from those of the distillate.
Meeks also suggests that these mice died of infection. First, if they had died of infection, this would be an important finding because only mice exposed to the distillate or CS-D4 died or developed evidence of tissue injury. However, the histopathologic picture is not one of infection. The histopathology of the liver showed a classic pattern of chemically induced cell death, and the lung lesions were not typical of bronchopneumonia or lobar pneumonia.
Meeks raises the question of metabolism and clearance. He is accurate that we do not cite any of the references he has provided in our discussion. We were in error in not including the contribution of McKim et al. (12) We believe that much more work on the low molecular weight cyclosiloxanes is necessary. Inhalation studies like the one referred to by Meeks, ingestion studies like the one summarized by Lukasiak et al., and injection studies are all necessary to develop an understanding of the biologic importance of these agents.
We are confident that our paper represents an important contribution to the study of silicone toxicology and hope that it will encourage many additional studies in this area. 
